Hot spot analysis of ESMO tumor conference in 2019

Tumor, as a chronic disease that has plagued human beings for many years and is becoming more and more rampant, its research progress can be said to affect everyone's heart ESMO annual meeting is one of the most professional and famous oncology conferences in Europe and even in the world Each session of ESMO will have a profound impact on the overall situation of the pharmaceutical industry ESMO Congress held by ESMO (European Society for Medical Oncology) is one of the most professional and famous oncology conferences in Europe and even in the world It carries the most advanced technology and the most authoritative academic exchanges in the medical field Since its establishment in 1975, the actual number of participants in each ESMO meeting has exceeded 25000, and the number of members has exceeded 23000 Experts and scholars from more than 150 countries have gathered to share and discuss the progress and hot topics in the field of cancer diagnosis and treatment in recent years In 2019, ESMO progress was held in Barcelona, Spain, for 5 days (September 27-october 1), including 287 agenda topics, covering biotherapy, immunotherapy, gene therapy and other new therapies In addition to the home conference, some branches are also preparing and holding one after another, such as the Asian branch held in Singapore on November 22-24, the immune branch held in Geneva on December 11-14, etc The most exciting and valuable part of the ESMO meeting is the summary sharing of the research progress of each team Figure 2 number of PD-1 / PD-L1 related literature published by PubMed in 2000-2019 Source: clinicaltrials.gov, Flint creation For PD-1 / PD-L1 therapy (PubMed's relevant publications have increased sharply year by year), Flint creation, through the data acquisition and analysis of clinicaltrials.gov, partially displays the important relevant research results in this session （1） Lung cancer 1 Small cell lung cancer Imprower133: as the first attempt in recent years, this study proved that immunocombination chemotherapy performed better than single chemotherapy in the survival rate of patients with small cell lung cancer, and PD-L1 expression did not show correlation in this result Caspiantrial: recently updated results from this study show that overall survival rates are significantly better in the combination of platinum and durvalumab, and there is no correlation between this result and PD-L1 expression Alter 1202: in patients with advanced small cell lung cancer who have received at least first-line and second-line treatment, anlotinib has shown significant efficacy in overall survival 2 Non-small cell lung cancer Checkmate 227: comparing the efficacy of nivolumab with chemotherapy in patients with NSCLC, the former showed better overall survival rate, and the difference remained after two years For patients with advanced NSCLC, if the expression of PD-L1 is not considered, the immunotherapy combination of nivolumab and ibilimumab may be an effective scheme compared with a variety of front-line therapies （2） Stomach cancer Attraction-3: This study shows for the first time that nivolumab can improve the survival rate of patients with esophageal squamous cell carcinoma, and has better tolerance than traditional chemotherapy in the second-line treatment Keynote-062: in the comparison of the first-line treatment of adenocarcinoma at the gastroesophageal junction, there was no significant difference in the effectiveness and safety of chemotherapy and immunotherapy (pembrolizumab) The non difference was mainly reflected in the overall survival rate, quality of life, and symptom control （3） Breast cancer Monaleesa-3: This study demonstrates that the combination therapy of fulvestrant and ribociclib significantly improves the progression free survival rate in ER + / HER2 like metastatic breast cancer treatment compared with fulvestrant alone Keynote-522: pembrolizumab combination chemotherapy shows two important advantages of complete pathological remission and event-free survival rate for early triple negative breast cancer After FDA approval, pembrolizumab may become the next standard treatment （4） Bladder cancer Card: in this study, compared with abiraterone / enzalutamide, cabazitaxel showed far more efficacy than second-generation hormone drugs in the treatment of metastatic castration resistant prostate cancer Its advantages were reflected in progression free survival rate, overall survival rate, and quality of life 1.ESMO Award This year's ESMO award was excerpted by Professor Eric van cutsem His peer-reviewed articles published in various university journals are numerous PubMed alone contains 340 articles, with more than 20000 citations His outstanding contribution in the field of gastrointestinal cancer makes him recognized as the "pioneer" in the field Professor Eric van cutsem has been working in the European Organization for research and treatment of cancer – gastroenteric cancer (eortc-gi) group for many years This research organization has participated in and completed many major clinical studies in the field of gastric cancer, including the innovation-trial 2 ESMO Lifetime Achievement Award The winner of the ESMO lifetime achievement award is Dr Angelo Di Leo Since 2003, Dr Angelo Di Leo has been the chairman of the oncology department of Prato hospital in Italy, and is still on the front line Over the years, his deep work in the field of breast cancer has been unanimously recognized, and he pioneered the field of biological research In addition, he is also a member of the Education Committee of ASCO (American Society of Clinical Oncology) He adheres to field research and contributes to the cultivation of young generation of experts 3 ESMO Women for Oncology Award ESMO women for oncology award is probably the most special honor of this year, which aims to honor and salute the women scholars who are on the hard line Professor Cristiana Sessa from Switzerland won the award She is not only a gynecological oncologist, but also tirelessly guides and educates young female scholars, and leads them to become a powerful force in the field of cancer research She believes that young female scholars should be valued, and they should be prepared to take on more and greater responsibilities 4 ESMO Translational Research Award The winner of ESMO translational research award is Professor Charles Swanton The most outstanding achievement of him and his team is to prove that the direction of tumor evolution coincides with that of Darwin's natural selection and branch evolution, which theoretically proves the root cause of tumor treatment failure Translational medicine (also known as translational medicine) refers to the integrated analysis of basic medical research and clinical diagnosis of the hospital bed, and the development of new diagnosis and treatment methods and specific drug development, so as to carry out personalized treatment for specific diseases or patients Professor Charles Swanton and his team have begun to make specific attempts to this theory on NSCLC (non-small cell lung cancer) (tracerx-nct01888601 and Darwin ii-nct02314481), and are expected to get corresponding experimental results in 2023.